Astellas Pharma
Astellas Pharma is one of Japan’s leading pharmaceutical companies, established in 2005 through the merger of Yamanouchi Pharmaceutical and Fujisawa Pharmaceutical. It consistently ranks among Japan’s top drugmakers by revenue and market presence, with a strong focus on global R&D, particularly in oncology and urology. Astellas Pharma is making headlines in 2026 with major PADCEV regulatory approvals, a new five-year growth strategy, patent settlements, and efforts to offset upcoming revenue declines. The company also partnered with Vir Biotechnology to co-develop PSMA-targeting prostate cancer therapy VIR-5500 in a deal worth up to $1.7 billion, including $335 million in upfront and near-term payments.
"Astellas is strengthening its growth pipeline through strategic innovation, partnerships, and regulatory wins"
Enfortumab vedotin (PADCEV)
Mechanism of Action: Tubulin polymerisation inhibitors Drug Class: Monoclonal antibodies Indication: Muscle-invasive bladder cancer
Approved: The U.S. FDA and European Commission approved PADCEV plus Keytruda for muscle-invasive bladder cancer, introducing a first-of-its-kind platinum-free treatment option. Astellas submitted a New Drug Application in Japan for fezolinetant to treat menopausal vasomotor symptoms, expanding its women's health footprint globally. Financial impact: PADCEV’s expanded use with Keytruda in Japan is boosting Astellas Pharma’s revenue and helping offset upcoming Xtandi patent expirations.
PADCEV is Astellas’ standout growth driver, with U.S. sales rising 33% year-on-year to ¥38 billion in Q4 following its Keytruda combination approval. A potential expansion into cisplatin-eligible MIBC patients could further strengthen its growth. PADCEV is a key high-margin asset in Astellas’ 2026–2030 Corporate Strategic Plan (CSP2026), supporting the company’s goal of doubling contributions from its strategic brands.
PADCEV Revenue Surges, Cementing Its Role as a Key Oncology Growth Driver
PADCEV revenue has grown rapidly, rising from $222.4 million in 2020 to $1.94 billion in 2025. Growth accelerated sharply after 2022, reaching $1.18 billion in 2023 and $1.59 billion in 2024. In Q1 2026, PADCEV generated $591 million, up 39% year-on-year, reinforcing its position as a key oncology growth driver for Pfizer and Astellas.
Seven-year market revenue of PADCEV (2020-Q12026)
Fig 6: Market revenue of PADCEV
Astellas Pharma-Vir Biotechnology
Type: Strategic collaboration
Focus: VIR-5500
Deal value: $1.7 billion
Financial impact: Astellas and Vir Biotechnology partnered to advance VIR-5500, a PSMA-targeting CD3 T-cell engager for prostate cancer, strengthening Astellas’ oncology pipeline and prostate cancer portfolio.
Astellas Pharma and Vir Biotechnology entered a global collaboration in February 2026 to co-develop VIR-5500, a PSMA-targeting CD3 T-cell engager for prostate cancer. The deal includes $335 million in upfront and near-term payments and could reach $1.7 billion, with Astellas funding 60% of development costs and receiving rights to the program outside the U.S.
Astellas Pharma and Vir Biotechnology entered a global collaboration in February 2026 to co-develop VIR-5500, a PSMA-targeting CD3 T-cell engager for prostate cancer. The deal includes $335 million in upfront and near-term payments and could reach $1.7 billion, with Astellas funding 60% of development costs and receiving rights to the program outside the U.S.
"As the market expands from $11.5 billion in 2020 to a forecasted $15.2 billion in 2026, Astellas Pharma is positioning itself for future revenue growth through its global partnership with Vir Biotechnology and the promising VIR-5500 program."
Seven-year market revenue of Astellas Pharma (2020-2026)
Fig 7: Market revenue of Astellas Pharma
Advancing innovation through a robust late-stage and emerging pipeline
Astellas Pharma maintains a diversified development pipeline across oncology, nephrology, rare diseases, ophthalmology, urology, women's health, and digital therapeutics. The portfolio demonstrates a strong focus on innovative treatment modalities, including bispecific antibodies, antibody-drug conjugates (ADCs), T-cell engagers, cell therapies, gene therapies, and targeted small molecules, with oncology representing the largest area of development activity.
Several key assets have advanced into Phase 3 development, highlighting the maturity and commercial potential of Astellas' late-stage pipeline. Notable Phase 3 programs include
- roxadustat for anemia associated with chronic kidney disease in pediatric patients;
- gilteritinib (XOSPATA) in multiple acute myeloid leukemia (AML) settings, including post-chemotherapy maintenance, post-hematopoietic stem cell transplant maintenance, newly diagnosed AML, and pediatric AML;
- setidegrasib (ASP3082), a KRAS G12D degrader for pancreatic ductal adenocarcinoma; and
- zolbetuximab (VYLOY) for gastric and gastroesophageal junction adenocarcinoma in combination with pembrolizumab and chemotherapy.
Additional Phase 3 assets include
- mirabegron for pediatric neurogenic detrusor overactivity,
- fezolinetant (VEOZAH) for vasomotor symptoms in breast cancer patients receiving endocrine therapy, and
- pudexacianinium chloride (ASP5354) for intraoperative ureter visualisation.
Overall, Astellas Pharma's pipeline balances a strong late-stage portfolio with a robust early-stage innovation engine, positioning the company for continued growth through differentiated therapies addressing significant unmet medical needs across multiple therapeutic areas.
